These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38898120)

  • 1. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
    Peters S; Gadgeel SM; Mok T; Nadal E; Kilickap S; Swalduz A; Cadranel J; Sugawara S; Chiu CH; Yu CJ; Moskovitz M; Tanaka T; Nersesian R; Shagan SM; Maclennan M; Mathisen M; Bhagawati-Prasad V; Diarra C; Assaf ZJ; Archer V; Dziadziuszko R
    Nat Med; 2024 Jul; 30(7):1923-1932. PubMed ID: 38898120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
    Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
    Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
    J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial Cell-Free DNA Sequencing in
    Choudhury NJ; Jun Woo H; Chen M; Shah R; Donoghue M; Berger M; Drilon A
    JCO Precis Oncol; 2024 Jun; 8():e2300721. PubMed ID: 38848521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
    Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
    [No Abstract]   [Full Text] [Related]  

  • 6. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    Fan Y; Drilon A; Chiu CH; Loong HHF; Siena S; Krzakowski M; Dziadziuszko R; Zeuner H; Xue C; Krebs MG
    Clin Lung Cancer; 2024 Mar; 25(2):e81-e86.e4. PubMed ID: 38245456
    [No Abstract]   [Full Text] [Related]  

  • 7. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
    Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE
    Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study.
    Yang JJ; Zhou J; Liu SM; Li M; Zhang Z; Cheng Y; Fan Y; Pan H; Wang B; Chen G; Wang K; Jiang L; Hu Y; Shi J; Dong X; Ding C; Liu Y; Liu Z; Liao W; Li W; Wang J; Yi S; Zhao Q; Zang A; Chen Y; Cui J; Luo P; Shen X; Sun M; Wang C; Wu YL;
    Lancet Respir Med; 2024 Sep; 12(9):671-680. PubMed ID: 39059398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRUST-II: a global phase II study of taletrectinib in
    Nagasaka M; Ohe Y; Zhou C; Choi CM; Yang N; Liu G; Felip E; Pérol M; Besse B; Nieva J; Raez L; Pennell NA; Dimou A; Marinis F; Ciardiello F; Seto T; Hu Z; Pan M; Wang W; Li S; Ou SI
    Future Oncol; 2023 Jan; 19(2):123-135. PubMed ID: 36877099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
    Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
    J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
    Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
    ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE
    Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating entrectinib as a treatment option for non-small cell lung cancer.
    Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Opin Pharmacother; 2020 Nov; 21(16):1935-1942. PubMed ID: 32736487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
    Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
    Wu YL; Yang JC; Kim DW; Lu S; Zhou J; Seto T; Yang JJ; Yamamoto N; Ahn MJ; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner KD; Goto K
    J Clin Oncol; 2018 May; 36(14):1405-1411. PubMed ID: 29596029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
    Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
    Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
    Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.